Literature DB >> 24591085

MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection?

Ewelina Maria Kałużna1.   

Abstract

MicroRNAs (miRNAs) are a class of small, evolutionarily conserved, noncoding RNA that regulate several important cellular processes. The versatility of these molecules allowed the accurate predictions that they would also affect the replication and life cycle of HCV. In this review, emphasis has been given to two selected miRNAs: miR-155 and miR-196b. Recent data indicate that miR-155 is overexpressed in HCV-infected patients, inducing an inflammatory state, and promoting virus replication and persistence even after the completion of antiviral treatment. It is also associated with the increased proliferation and inhibited apoptosis of hepatocytes, which promotes the growth of liver tumors. In contrast, miR-196b is reported as a factor inhibiting HCV replication with cytoprotective, anti-inflammatory, and antioxidant properties. Growing evidence suggests that these molecules could be used as potential prognostic and predictive factors and their antagonists or mimics as a promising therapeutic approach in HCV-infected patients.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24591085     DOI: 10.1002/rmv.1785

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  11 in total

Review 1.  MicroRNA 155 and viral-induced neuroinflammation.

Authors:  Laura L Dickey; Timothy M Hanley; Thomas B Huffaker; Andrew G Ramstead; Ryan M O'Connell; Thomas E Lane
Journal:  J Neuroimmunol       Date:  2017-01-24       Impact factor: 3.478

2.  Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.

Authors:  Nazim Hussain; Nimrah Farooq; Muhammad Maqsood; Muhammad Shahid Riaz Rajoka; Muhammad Bilal
Journal:  Arch Microbiol       Date:  2021-03-03       Impact factor: 2.552

Review 3.  MicroRNA-mediated interactions between host and hepatitis C virus.

Authors:  Hu Li; Jian-Dong Jiang; Zong-Gen Peng
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development.

Authors:  J P Ren; R S Ying; Y Q Cheng; L Wang; M El Gazzar; G Y Li; S B Ning; J P Moorman; Z Q Yao
Journal:  J Viral Hepat       Date:  2016-03-23       Impact factor: 3.728

Review 5.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  Regulation of viral oncogenesis by microRNAs.

Authors:  Xiaojie Xu; Qinong Ye
Journal:  Mol Cell Oncol       Date:  2014-09-02

7.  MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.

Authors:  Amal Ahmed Mohamed; Abdellah Abosrie Ali Omar; Rehab R El-Awady; Sally Mohamed Aboelsayed Hassan; Waleed Mohamed Soliman Eitah; Rehab Ahmed; Amir Khater; Omnia Mohamed Saad Tantawi; Ahmed Abdelhafeez Mohamed
Journal:  J Transl Int Med       Date:  2020-05-09

8.  Autophagy, Mitophagy and MicroRNA Expression in Chronic Hepatitis C and Autoimmune Hepatitis.

Authors:  Tímea Szekerczés; Alíz Gógl; Ildikó Illyés; József Mandl; Katalin Borka; András Kiss; Zsuzsa Schaff; Gábor Lendvai; Klára Werling
Journal:  Pathol Oncol Res       Date:  2020-03-02       Impact factor: 3.201

9.  MicroRNA-21 was a promising biomarker for lung carcinoma diagnosis: An update meta-analysis.

Authors:  Haiyan Wang; Jia Xu; Ling Ding
Journal:  Thorac Cancer       Date:  2021-11-27       Impact factor: 3.500

10.  Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.

Authors:  Anastasia Hyrina; Andrea D Olmstead; Paul Steven; Mel Krajden; Edward Tam; François Jean
Journal:  EBioMedicine       Date:  2017-08-24       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.